Stories about Forschung

Subscribe to topic

Subscribe to Forschung

05.02.2019 – 10:00
Jennewein Biotechnologie GmbH
Jennewein Biotechnologie and Yili Group join forces in China for microbiome research and human milk oligosaccharides to bring innovation to the largest baby food market
Hohhot, China & Rheinbreitbach, Germany (ots) - - China represents the largest market for baby food globally - Human milk oligosaccharides are key for the development of a healthy infant microbiome Jennewein Biotechnologie GmbH, the global leader in the research and manufacture of human milk oligosaccharides (HMO), ...
10.01.2019 – 11:10
nutriCARD
Cardiovascular diseases and nutrition in Europe: every second to third premature death preventable
13.12.2018 – 10:50
Dialogue of Civilizations Research Institute
DOC Research Institute launches its first essay competition for young international researchers
Berlin (ots) - The Dialogue of Civilizations Research Institute (DOC) announces the launch of 'My Country, Our World in 2030', an essay competition for researchers under the age of 28 from Council of Europe member states and the Commonwealth of Independent States (CIS). The competition is part of a project exploring young people's expectations for the future of their ...
29.10.2018 – 14:00
City of Qingdao
2
International Symposium on Kang Youwei's Calligraphic Study was held in Qingdao, China
22.10.2018 – 10:54
KfW IPEX-Bank
KfW IPEX-Bank and Commerzbank finance third expedition ship for Hapag-Lloyd Cruises
Frankfurt am Main (ots) - - HANSEATIC spirit to be built at Norwegian VARD shipyard - Support for Europe's export industry in global competition - Cutting-edge technology for sustainability in expedition cruising KfW IPEX-Bank and Commerzbank are financing a third expedition ship for Hapag-Lloyd Cruises. The Hamburg-based subsidiary of TUI Group already contracted the ...
11.10.2018 – 12:00
Debiopharm International SA
Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic product in Oncology
Lausanne, Villigen, Switzerland (ots) - Debiopharm International SA (Debiopharm), a Swiss-based biopharmaceutical company and the Paul Scherrer Institute (PSI), the largest research institute for natural and engineering sciences in Switzerland, today announced a collaboration to pursue the development of a ...
07.08.2018 – 10:47
ECMWF Copernicus Services
ECMWF Copernicus C3S monthly update: Hot and dry weather conditions in July
Reading, England (ots) - July 2018 surface air temperature - Many regions around the globe saw much above average temperatures, due in part to sustained heatwaves, for instance in northern Europe, northern China, Korea and Japan. - Europe saw its second warmest July on record, half a degree cooler than the warmest July (2010), - globally it was the third warmest July, ...
24.07.2018 – 12:00
Jennewein Biotechnologie GmbH
EIB provides funding to Jennewein
Rheinbreitbach (ots) - The European Investment Bank (EIB) provides new financing of EUR 15 million to Jennewein Biotechnologie GmbH, a highly innovative German company that offers a breakthrough technology for the production of rare functional sugars for a wide range of applications, including nutritional, pharmaceutical and cosmetic products. The Company is also a leading manufacturer of human milk oligosaccharides (HMOs), which form an essential part of human mother milk ...
25.06.2018 – 11:58
Dermalog Identification Systems GmbH
Leading iris recognition from DERMALOG
21.06.2018 – 11:00
Grünenthal Group
Grünenthal, Lead Discovery Center and Max Planck Society enter into a research collaboration on Charcot-Marie-Tooth 1A (CMT1A)
Aachen, Dortmund and Göttingen (ots) - Grünenthal, Lead Discovery Center GmbH (LDC), Max-Planck Innovation and Max Planck Institute of Experimental Medicine (MPI-EM) have entered into a research collaboration to develop novel therapies for patients suffering from Charcot-Marie-Tooth 1A (CMT1A), an inherited ...
12.06.2018 – 13:00
Grünenthal Gruppe
Grünenthal Initiates Pivotal Phase III Trials in Complex Regional Pain Syndrome
Aachen, Germany (ots) - Grünenthal announced today that first patients have been enrolled in two trials of the company's pivotal phase III program investigating neridronate for the treatment of Complex Regional Pain Syndrome (CRPS). These two trials, KF7013-02 and KF7013-04, are investigating the efficacy and safety of neridronate in 360 patients with CRPS. ...
05.06.2018 – 14:00
IMI-PainCare
IMI-PainCare: Public-private partnership tackles major challenges in the care of pain patients
Aachen (ots) - To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organizations and pharmaceutical industry launched the research project "IMI-PainCare - Improving the care of patients suffering from acute or ...
08.05.2018 – 09:00
Debiopharm International SA
FDA Grants Fast Track designation to Debiopharm International's Debio 1347 for the treatment of patients with unresectable or metastatic tumors with a specific FGFR gene alteration
Lausanne, Switzerland (ots) - Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Debio 1347, an FGFR 1-3 Inhibitor, for the ...
04.05.2018 – 16:00
Jennewein Biotechnologie GmbH
Jennewein Biotechnologie: First clinical trial of a blend of human milk oligosaccharides emulating the human profile of infant formula
23.04.2018 – 14:21
Hamburg Marketing GmbH
2
Innovations from Hamburg: largest 3D-printed functional component & world's largest X-ray at Hannover Messe
23.04.2018 – 12:00
Grünenthal Group
Dr. Philip Just Larsen Appointed Chief Scientific Officer (CSO)
Aachen (ots) - Grünenthal announced today that Philip Just Larsen has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal's research and development organization on 1 July 2018. Currently, Philip holds the role of Global Head of Diabetes Research and Translational Medicine and Chief Scientific Officer at Sanofi's German Hub in Frankfurt. Philip is a senior leader with extensive experience in drug discovery and development including successful transition into the clinic. He is a Medical Doctor trained in internal ...
09.04.2018 – 09:30
Grünenthal Group
Grünenthal and KU Leuven join forces to develop an innovative non-opioid pain treatment
Aachen and Leuven, Belgium (ots) - Grünenthal, the Katholieke Universiteit Leuven's Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LICR) announced today that they have entered into a research collaboration for the development of novel non-opioid drug candidates for the treatment of painful diseases with a high unmet medical need. The partnership builds on lead compounds jointly developed by CD3 and LICR as well as on the know-how of Thomas Voets (LICR) and Joris Vriens (LICR), leading experts in the ...
07.03.2018 – 13:45
Campus Klinik an der Ruhr-Universität Bochum
2
Brain damage in newborns - unique index discovered / Head circumference determines brain damage in newborns!
One document
15.02.2018 – 09:00
Debiopharm International SA
Debiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc. / ABAC develops new targeted antibiotics for patients with severe infections
Lausanne (ots) - Debiopharm Group (TM) announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the ...
05.12.2017 – 07:48
Grünenthal Group
New partnership for the commercialization of Nucynta® in the U.S. territory
Aachen (ots) - The Grünenthal Group announced today that Nucynta® (tapentadol) will be commercialized in the U.S. territory by Collegium Pharmaceutical, Inc., instead of Depomed, Inc., from 2018 onwards. In recent months, Depomed has been struggling to grow Nucynta®. Depomed executes its strategy to transform into a specialty pharmaceutical company with less focus ...
28.11.2017 – 14:00
Debiopharm International SA
GenePOC Launches its GenePOC(TM) CDiff test in the United States / GenePOC announces the launch and FDA clearance of its Clostridium difficile molecular test in US
Québec, Canada (ots) - GenePOC Inc. (GenePOC), a member of the Debiopharm Group(TM), is proud to announce the launch of its 2nd FDA cleared assay in less than 6 months, GenePOC(TM) CDiff, for use on the revogene(TM) instrument. The GenePOC CDiff test targets the toxin B gene of toxigenic C. difficile strains in ...
12.10.2017 – 09:01
Debiopharm International SA
GenePOC Launches its new GenePOC(TM) GBS DS test / GenePOC announces the launch of its Group B Streptococcus Direct Swab (DS) molecular test in Europe
Québec, Canada (ots) - GenePOC, Inc. (GenePOC), a member of the Debiopharm Group, is proud to announce the launch of its 2nd assay this year, GenePOC(TM) GBS DS[1], for use on the revogene(TM) instrument. GenePOC GBS DS at intrapartum will aid to minimize the risk of GBS transmission from the mother to their ...
04.10.2017 – 11:00
EUMETSAT
Eyes over the Storms - EUMETSAT explains the crucial role of satellites in monitoring ocean influence on weather, climate
Darmstadt (ots) - EUMETSAT re-launches EU-funded MOOC On the surface, the devastation recently wrought by hurricanes, the fluctuations of marine phytoplankton in global oceans and the impact of sea surface temperature in the Pacific on weather in Europe might not seem to have much in common. Yet they are all ...
03.10.2017 – 14:01
Debiopharm International SA
Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur(TM), Triptorelin 6-month Formulation, for Treatment of Central Precocious Puberty (CPP)
Atlanta, GA, USA and Lausanne, Switzerland (ots) - Triptodur(TM), (triptorelin) extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty associated with CPP via a once every six-month intramuscular (IM) injection. Arbor Pharmaceuticals, LLC, a U.S. based specialty ...
29.09.2017 – 08:01
Debiopharm International SA
The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2017 JCA-Mauvernay Award
Lausanne (ots) - The 'JCA-Mauvernay Award 2017' is awarded to Doctors Yasuhiro Yamada and Hiroyoshi Nishikawa Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a Swiss-based global biopharmaceutical company, will be presenting the 'JCA-Mauvernay Award' on September 30 to Doctors Yasuhiro Yamada from the ...
01.09.2017 – 10:00
Hamburg Marketing GmbH
European XFEL: world's largest X-ray laser to launch in Hamburg
10.05.2017 – 11:00
Grünenthal Group
Grünenthal opens Innovation Hub in Boston as next step in strategy to drive external innovation in pain, specialty therapeutics and medical devices forward
Aachen, Germany (ots) - - Grünenthal's new Innovation Hub in Greater Boston, U.S., shall accelerate easier access to and close collaboration with leading scientists and institutions - Grünenthal brings fully integrated R&D capabilities in pain to this community - there is no other company with so much focus on ...

123Next